Please login to the form below

Not currently logged in
Email:
Password:

Takeda acquires Nycomed

Takeda Pharmaceutical Company has completed a €9.6bn takeover of Nycomed

Takeda Pharmaceutical Company has acquired Nycomed for €9.6bn on a cash-free, debt-free basis.

The boards of directors of each company unanimously approved the transaction that is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's US dermatology business.

Takeda said: "This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 mid-range plan. Takeda has its strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialisation capability."

The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease, which is expected to be a major source of revenue growth for Takeda.

19th May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics